Base de dados : LILACS
Pesquisa : D12.644.276.374.500.800 [Categoria DeCS]
Referências encontradas : 737 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 74 ir para página                         

  1 / 737 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-973620
Autor: Silvestre, Marilene Chaves; Reis, Vitor Manoel Silva dos.
Título: Evaluation of the profile of inflammatory cytokines, through immunohistochemistry, in the skin of patients with allergic contact dermatitis to nickel in the acute and chronic phases
Fonte: An. bras. dermatol;93(6):829-835, Nov.-Dec. 2018. tab, graf.
Idioma: en.
Resumo: Abstract: Background: Allergic contact dermatitis to ion nickel (Ni+2) is an inflammatory dermatosis, common in industrialized countries. It involves the activation of nickel-specific T-cells, followed by proliferation and induction of a mixed profile of both proinflammatory and regulatory cytokines, suggesting that several T-cell subtypes (helper - Th and cytotoxic - Tc) are involved. A broader understanding of the cytokine profile may lead to new therapeutic approaches. Objectives: This study aimed to analyze the cytokines TNF-α, INF-γ, IL-2, IL-4, IL-10, IL-13, IL-17 and IL-23 using the immunohistochemistry technique in order to try to identify their prevalence in chronic and acute eczema of patients with allergic contact dermatitis to Ni+2. Methods: We performed an immunohistochemical study for eight cytokines in 20 patients with Ni+2 allergic contact dermatitis, biopsied at the site of chronic eczema, triggered by the patient's daily contact with Ni+2, and at the site of acute eczema caused by nickel sulfate, 48 hours after applying the contact test. Results: The stained samples showed positive results for the eight cytokines studied. TNF-α, IFN-γ, IL-4, IL-13 and IL-17 had a higher prevalence in chronic eczema, IL-2 and IL-23 in acute eczema, and IL-10 presented a similar prevalence in both acute and chronic eczema. However, these prevalences were statistically significant only for IL-4 and IL-13. Study Limitations: Small sample size. Conclusions: In chronic and acute eczema, we observed the presence of a mixed cytokine profile of the T cell subtypes (Th/Tc), suggesting that the responses are expressed at the same time.
Descritores: Citocinas/análise
Interleucinas/análise
Interferon gama/análise
Fator de Necrose Tumoral alfa/análise
Dermatite Alérgica de Contato/imunologia
Níquel/efeitos adversos
-Biópsia
Imuno-Histoquímica
Doença Aguda
Doença Crônica
Estudos Prospectivos
Citocinas/imunologia
Interleucinas/imunologia
Interferon gama/imunologia
Fator de Necrose Tumoral alfa/imunologia
Dermatite Alérgica de Contato/etiologia
Dermatite Alérgica de Contato/patologia
Níquel/imunologia
Limites: Seres Humanos
Masculino
Feminino
Adulto
Meia-Idade
Idoso
Adulto Jovem
Tipo de Publ: Estudo Observacional
Responsável: BR1.1 - BIREME


  2 / 737 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-837982
Autor: Carvalho, André Vicente Esteves de; Romiti, Ricardo; Souza, Cacilda da Silva; Paschoal, Renato Soriani; Milman, Laura de Mattos; Meneghello, Luana Pizarro.
Título: Psoriasis comorbidities: complications and benefits of immunobiological treatment
Fonte: An. bras. dermatol;91(6):781-789, Nov.-Dec. 2016.
Idioma: en.
Resumo: Abstract During the last decade, different studies have converged to evidence the high prevalence of comorbidities in subjects with psoriasis. Although a causal relation has not been fully elucidated, genetic relation, inflammatory pathways and/or common environmental factors appear to be underlying the development of psoriasis and the metabolic comorbidities. The concept of psoriasis as a systemic disease directed the attention of the scientific community in order to investigate the extent to which therapeutic interventions influence the onset and evolution of the most prevalent comorbidities in patients with psoriasis. This study presents scientific evidence of the influence of immunobiological treatments for psoriasis available in Brazil (infliximab, adalimumab, etanercept and ustekinumab) on the main comorbidities related to psoriasis. It highlights the importance of the inflammatory burden on the clinical outcome of patients, not only on disease activity, but also on the comorbidities. In this sense, systemic treatments, whether immunobiologicals or classic, can play a critical role to effectively control the inflammatory burden in psoriatic patients.
Descritores: Psoríase/tratamento farmacológico
Anticorpos Monoclonais/uso terapêutico
-Doenças Cardiovasculares/tratamento farmacológico
Comorbidade
Fatores de Risco
Fator de Necrose Tumoral alfa/antagonistas & inibidores
Síndrome Metabólica/tratamento farmacológico
Diabetes Mellitus/tratamento farmacológico
Dislipidemias/tratamento farmacológico
Obesidade Abdominal/tratamento farmacológico
Hepatopatia Gordurosa não Alcoólica/tratamento farmacológico
Hipertensão/tratamento farmacológico
Limites: Seres Humanos
Tipo de Publ: Revisão
Responsável: BR1.1 - BIREME


  3 / 737 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-975978
Autor: Gheibi, Shahsanam; Hashemi, Seyyed Rahim; Karimipour, Mojtaba; Motlagh, Bahman Mansouri; Ghaleh, Hadi Esmaeili Gouvarchin.
Título: Synergistic effects of hydro extract of jujube fruit in combination with Mesalazine (orally) and Asacol (intra-colonic) administration in ameliorating animal model of ulcerative colitis / Efeitos sinérgicos do extrato aquoso da fruta da jujuba em combinação com administração de Mesalazina (via oral) e Asacol (intracolônico) na melhora de colite ulcerativa em modelo animal
Fonte: J. coloproctol. (Rio J., Impr.);38(4):275-282, Oct.-Dec. 2018. tab, graf, ilus.
Idioma: en.
Resumo: ABSTRACT This study was done to investigate the synergistic impacts hydro extract of jujube fruit in combination with Mesalazine (orally) and Asacol (intra-colonic) administration in ameliorating animal model of ulcerative colitis (UC). After the induction of UC and with the development of signs, the treatment groups daily received the hydro extract of jujube fruit (200 mg/kg, orally, enema), Mesalazine (30 mg/kg, orally) and Asacol (10 mg/kg, enema). After 10 days, rats were euthanized and were studied. Findings indicated a significant increase in Myeloperoxidase (161.66 ± 10.40), Nitric oxide (216.01 ± 17.55), IL-6 (138.54 ± 7.02), and TNF-α (123.87 ± 9.80) colon tissue levels and pathological damage of positive control group compared with the negative control group. Hydro extract of jujube fruit in combination with Mesalazine (orally) and Asacol (intra-colonic) group represented a higher capability in significantly decreasing Myeloperoxidase (73.33 ± 9.07), Nitric oxide (81.66 ± 10.50), IL-6 (51.69 ± 5.19), TNF-α (30.59 ± 5.50) levels and pathological damage in compared with the other treatment groups. Considering accessibility and affordability of jujube fruit and the side effects of routine drugs, taking a combination of jujube fruit with low doses of routine pharmaceutical drugs can improve and cure ulcerative colitis disease.

RESUMO Este estudo foi realizado para investigar os impactos sinérgicos do extrato aquoso do fruto da jujuba em combinação com a administração de Mesalazina (por via oral) e Asacol (intracolônico) na melhora do modelo animal de colite ulcerativa. Após a indução da colite ulcerativa e com o desenvolvimento de sinais, os grupos de tratamento receberam diariamente o extrato aquoso do fruto da jujuba (200 mg/kg, via oral, enema), Mesalazina (30 mg/kg, via oral) e Asacol (10 mg/kg, enema). Após 10 dias, os ratos foram eutanasiados e estudados. Os achados indicaram um aumento significativo dos níveis de mieloperoxidase (161,66 ± 10,40), óxido nítrico (216,01 ± 17,55), IL-6 (138,54 ± 7,02) e TNF-α (123,87 ± 9,80) no tecido do cólon e dano patológico do grupo controle positivo comparado com o grupo controle negativo. O extrato aquoso da fruta de jujuba em combinação com Mesalazina (oral) e Asacol (intracolônico) representou maior capacidade de redução significativa dos níveis de mieloperoxidase (73,33 ± 9,07), óxido nítrico (81,66 ± 10,50), IL-6 (51,69 ± 5,19), TNF-α (30,59 ± 5,50) e dano patológico em comparação com os outros grupos de tratamento. Considerando a acessibilidade e disponibilidade do fruto da jujuba e dos efeitos colaterais dos medicamentos de rotina, tomar uma combinação de jujuba com baixas doses de medicamentos farmacêuticos de rotina pode melhorar e curar a colite ulcerativa.
Descritores: Colite Ulcerativa
Mesalamina
Ziziphus
-Preparações Farmacêuticas
Interleucina-6
Fator de Necrose Tumoral alfa
Peroxidase
Óxido Nítrico
Limites: Animais
Ratos
Responsável: BR545.3 - Biblioteca ICBS


  4 / 737 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1051406
Autor: Mattera, Maria Sara de Lima Coutinho.
Título: Avaliação do mecanismo epigenético por metilação do DNA e da expressão de GLUT4 em tecido muscular esquelético de ratos adultos, proles de ratas com doença periodontal / Evaluation of the epigenetic mechanism by DNA methylation and GLUT4 expression in skeletal muscle tissue of adult rats, prole of rats with periodontal disease.
Fonte: Araçatuba; s.n; 2019. 83 p. graf, tab, ilus.
Idioma: pt.
Tese: Apresentada a Universidade Estadual Paulista "Julio de Mesquita Filho". Faculdade de Odontologia de Araçatuba para obtenção do grau de Doutor.
Resumo: Atualmente, está bem estabelecido que o ambiente fetal está ligado à saúde materna, e estímulos ou agressões anormais durante a vida intra-uterina podem resultar em mudanças na fisiologia e metabolismo da prole, aumentando o risco de doenças na vida adulta. Tal fenômeno é conhecido como programação fetal. Alterações na metilação do DNA e expressão gênica são consideradas mecanismos moleculares responsáveis por esta programação. Estudos anteriores demonstraram que a doença periodontal (DP) materna promove resistência insulínica, aumento nas concentrações plasmáticas de citocinas, redução do conteúdo de GLUT4 e do seu índice de translocação para membrana plasmática em sua prole adulta. E citocinas, como por exemplo, o TNF-α, têm sido relacionadas com a redução da expressão de GLUT4 por meio da ativação do fator de transcrição nuclear κappa B (NF-κB). Além disso, esta citocina pode estimular algumas serinas quinases, incluindo IκB quinase (IKK), c-Jun amino-terminal kinase (JNK) e quinases reguladas por sinais extracelulares (ERKs) que estão envolvidas na resistência insulínica. Tais achados evidenciam a necessidade de realizar mais estudos para verificar os mecanismos envolvidos nestas alterações. Portanto, os objetivos do presente estudo foram avaliar em ratos adultos, proles de ratas com DP: 1) massa corpórea ao longo de 75 dias de idade; 2) glicemia e insulinemia; 3) expressão do RNAm da proteína transportadora de glicose GLUT4 e do IRS1 em muscular esquelético gastrocnêmio (MG); 4) o grau de metilação do DNA na região promotora do gene do GLUT4 em MG; 5) fosforilação das proteínas JNK, IKKα/ß, ERK 1/2, NF-κBp65 e NF-κBp50 e seus conteúdos totais em MG; 6) conteúdo total de TNF-α em MG. As ratas foram divididas em dois grupos: 1) com doença periodontal (DP), no qual esta doença foi induzida por meio de ligadura com fio de seda ao redor do 1º molar inferior; 2) ratas controle (CN). Após 7 dias da colocação da ligadura, as ratas de ambos os grupos foram colocadas para acasalamento, verificou-se diariamente, por esfregaço vaginal, o dia da copulação. As ratas prenhas foram separadas em caixas individuais. Quando os filhotes machos destas ratas completaram 75 dias, realizaram-se os experimentos: 1) glicemia e insulinemia; 2) expressão do RNAm do GLUT4 e do IRS1 em MG; 3) o grau de metilação do DNA na região promotora do gene do GLUT4 em MG; 4) fosforilação das proteínas JNK, IKKα/ß, ERK 1/2, NF-κBp65 e NF-κBp50 e seus conteúdos totais em MG; 5) conteúdo total de TNF-α em MG. Os resultados demonstraram que a doença periodontal materna promove na sua prole adulta baixo peso ao nascimento (BPN), resistência insulínica, aumento do conteúdo total de TNF-α em MG, aumento do grau de fosforilação de IKKα/ß, ERK 1/2, NF-κBp65 (grau de fosforilação e conteúdo) e NF-κBp50 em MG, diminuição na expressão gênica da proteína transportadora de glicose GLUT4 e aumento na expressão gênica do IRS1; porém não promove nessa prole alteração no grau de metilação do DNA na região promotora do gene do GLUT4, e no grau de fosforilação da proteína JNK em MG. Portanto, este estudo é de fundamental importância para o entendimento de alguns dos mecanismos envolvidos na relação entre a doença periodontal materna e resistência à insulina na prole adulta. Além disso, mostra que a saúde bucal materna ideal pode ajudar a prevenir doenças futuras na prole adulta(AU)

It is well established that the fetal environment is linked to maternal health, and abnormal stimuli or aggressions during intrauterine life can result in changes in the physiology and metabolism of offspring, increasing the risk of disease in adult life, this phenomenon is known as fetal programming. Changes in DNA methylation and gene expression are considered molecular mechanisms responsible for this programming. Previous studies have demonstrated that maternal periodontal disease (PD) promotes insulin resistance, increased plasma concentrations of cytokines, reduced GLUT4 content and its plasma membrane translocation index in its adult offspring. And cytokines, such as TNF-α, have been linked to reduced GLUT4 expression through the activation of nuclear transcription factor kappa B (NF-κB). In addition, this cytokine can stimulate some serine kinases including IκB kinase (IKK), c-Jun amino-terminal kinase (JNK) and extracellular signal­regulated kinases (ERKs) that are involved in insulin resistance. These findings evidenced the need for further studies to verify the mechanisms involved in these changes. Therefore, the objectives of the present study were to evaluate in adult rats, offspring of rats with PD: 1) birth weight and during the 75 days of age; 2) glycemia and insulinemia; 3) GLUT4 and IRS1 mRNA expression in skeletal muscle gastrocnemius (MG); 4) the degree of DNA methylation in the promoter region of the GLUT4 gene in MG; 5) phosphorylation of JNK, IKKα/ß, ERK 1/2, NF-κBp65 and NF-κBp50 proteins and their total contents in MG; 6) TNF-α content in MG. Female Wistar rats were distributed into a control group and an experimental periodontal disease group, in which the disease is induced by ligation with silk thread around the 1st molar. Seven days after ligature placement, animals from both groups mated and daily vaginal smears were taken to verify the presence of sperm. Pregnant rats were kept in individual cages. The body weights of the offspring were measured once weekly from birth until 75 days of age. When male offspring of these rats completed 75 days, the experiments were performed: 1) glycemia and insulinemia; 2) GLUT4 and IRS1 mRNA expression in skeletal muscle gastrocnemius (MG); 3) the degree of DNA methylation in the promoter region of the GLUT4 gene in MG; 4) phosphorylation of JNK, IKKα/ß, ERK 1/2, NF-κBp65 and NF-κBp50 proteins and their total contents in MG; 5) TNF-α content in MG. The results demonstrated that maternal periodontal disease promotes in its adult offspring low birth weight (LBW), insulin resistance, increased TNF-α content in MG, increased IKKα/ß, ERK 1/2, NF-κBp65 (phosphorylation status and content) and NF-κBp50 phosphorylation status in the MG, decrease in gene expression of GLUT4 and increase in IRS1 gene expression; but does not promote in this progeny change in the degree of DNA methylation in the promoter region of the GLUT4 gene, and JNK phosphorylation status in MG. Therefore, this study is of fundamental importance for the understanding of some of the mechanisms involved in the relationship between maternal periodontal disease and insulin resistance in adult offspring. In addition, it shows that ideal maternal oral health can help prevent future illnesses in adult offspring(AU)
Descritores: Doenças Periodontais
Proteínas Quinases
Resistência à Insulina
Fator de Necrose Tumoral alfa
Transportador de Glucose Tipo 4
-Saúde Bucal
Ratos Wistar
Epigenômica
Inflamação
Limites: Animais
Ratos
Responsável: BR186.1 - Biblioteca Honório Monteiro
BR186.1


  5 / 737 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Levy, Roger Abramino
Texto completo
Id: biblio-837917
Autor: Vasconcellos, Jaqueline Barbeito de; Pereira, Daniele do Nascimento; Vargas, Thiago Jeunon de Sousa; Levy, Roger Abramino; Pinheiro, Geraldo da Rocha Castelar; Cursi, Ígor Brum.
Título: Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis
Fonte: An. bras. dermatol;91(5,supl.1):137-139, Sept.-Oct. 2016. graf.
Idioma: en.
Resumo: Abstract The use of tumor necrosis factor antagonists (anti-TNF) has become a usual practice to treat various inflammatory diseases. Although indicated for the treatment of psoriasis, anti-TNF may paradoxically trigger a psoriasiform condition. We present a case of a female patient who, during the use of infliximab for rheumatoid arthritis, developed psoriasis. In an attempt to switch anti-TNF class, we observed a cumulative worsening of the lesions requiring suspension of the immunobiological agent and the introduction of other drugs for clinical control. The therapeutic challenge of this paradoxical form of psoriasis is the focus of our discussion. The use of another anti-TNF in these patients is a matter of debate among experts.
Descritores: Artrite Reumatoide/tratamento farmacológico
Psoríase/induzido quimicamente
Psoríase/patologia
Fator de Necrose Tumoral alfa/antagonistas & inibidores
Antirreumáticos/efeitos adversos
Infliximab/efeitos adversos
-Pele/patologia
Adalimumab/efeitos adversos
Limites: Seres Humanos
Feminino
Adulto
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME


  6 / 737 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-787309
Autor: Antonio, João Roberto; Sanmiguel, Jessica; Cagnon, Giovana Viotto; Augusto, Marília Silveira Faeda; Godoy, Moacir Fernandes de; Pozetti, Eurides Maria Oliveira.
Título: Infliximab in patients with psoriasis and other inflammatory diseases: evaluation of adverse events in the treatment of 168 patients
Fonte: An. bras. dermatol;91(3):306-310tab, graf.
Idioma: en.
Resumo: Abstract: Background: Psoriasis is immune-mediated chronic inflammatory disease with preference for skin and joints. The skin involvement occurs by hyperproliferation and abnormal differentiation of keratinocytes. It is associated with comorbidities, mainly related to the clinical manifestations of the metabolic syndrome. Increased TNF-alpha expression (TNF-α) is related to its pathophysiology. Infliximab is an intravenous drug that acts neutralizing the biological activity of TNF-α and prevents the binding of the molecule to the target cell receptor, inhibiting cell proliferation of psoriasis and other diseases mediated by TNF-α. A lot of infusion reactions have been described in the literature. Objective: To evaluate the adverse effects of intravenous treatment with infliximab, analyzing patients with psoriasis compared to those with other chronic inflammatory diseases (rheumatoid arthritis, ankylosing spondylitis, Crohn's disease and ulcerative colitis). Method: Analysis of medical records and adverse events of 168 patients undergoing infliximab infusion for psoriasis and chronic inflammatory diseases treatment. Results: 168 patients who have used infliximab were evaluated, 24 had psoriasis and 144 had chronic inflammatory diseases. Only 2 (8.3%) patients with psoriasis showed adverse events requiring treatment discontinuation, and just 6 (4.2%) female patients with chronic inflammatory diseases experienced adverse events. Conclusion: Infliximab is a safe drug, with a low percentage of adverse events and there were more adverse events in women with chronic inflammatory diseases and in patients who received more infliximab infusions.
Descritores: Psoríase/tratamento farmacológico
Antirreumáticos/efeitos adversos
Infliximab/efeitos adversos
-Artrite Reumatoide/tratamento farmacológico
Espondilite Anquilosante/tratamento farmacológico
Doença de Crohn/tratamento farmacológico
Fatores Sexuais
Estudos Transversais
Estudos Retrospectivos
Fator de Necrose Tumoral alfa/antagonistas & inibidores
Fator de Necrose Tumoral alfa/metabolismo
Infliximab/uso terapêutico
Limites: Seres Humanos
Masculino
Feminino
Adulto
Meia-Idade
Responsável: BR1.1 - BIREME


  7 / 737 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Id: lil-219951
Autor: Picaguà, Estela; Vera, Marìa Elisa; Watanabe, Tadashi.
Título: Producciòn del factor de necrosis tumoral en la enfermedad de Chagas / Tumor necrosis factor production in Chagas' disease.
Fonte: Asunciòn; EFACIM-JICA; oct. 1990. 51-7 p.
Idioma: es.
Descritores: Trypanosoma cruzi/parasitologia
Fator de Necrose Tumoral alfa/imunologia
Doença de Chagas/imunologia
Doença de Chagas/parasitologia
Responsável: PY2.1 - Centro de Documentación
PY3.1 SR 616.9363 M619a 1990


  8 / 737 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Módolo, Norma Sueli Pinheiro
Castiglia, Yara Marcondes Machado
Texto completo
Id: lil-787265
Autor: Marques, Christiane D'Oliveira; Diego, Luis Antonio dos Santos; Marcondes-Machado, Jussara; Amorim, Renée Lauffer; Carvalho, Lídia Raquel; Módolo, Norma Sueli Pinheiro; Braz, Leandro Gobbo; Castiglia, Yara Marcondes Machado.
Título: Serum concentrations and renal expressions of IL-1 and TNF-a early after hemorrhage in rats under the effect of glibenclamide
Fonte: Acta cir. bras;31(7):434-441tab, graf.
Idioma: en.
Resumo: ABSTRACT PURPOSE: To investigate changes in the serum concentration and renal expression of IL-1 and TNF-α cytokines in rats that received sevoflurane and glibenclamide prior to hemorrhage. METHODS: Two groups of sevoflurane-anesthetized Wistar rats (n=10): G1 (control) and G2 (glibenclamide, 1 µg/g i.v.); hemorrhage of 30% blood volume (10% every 10 min), with replacement using Ringer solution, 5 ml/kg/h. Serum concentrations of IL-1 and TNF-α were studied in the first hemorrhage (T1) and 50 min later (T2), renal expression, at T2. RESULTS: In serum, G1 TNF-α (pg/mL) was T1=178.6±33.5, T2=509.2±118.8 (p<0.05); IL-1 (pg/mL) was T1=148.8±31.3, T2=322.6±115.4 (p<0.05); in G2, TNF-α was T1=486.2±83.6, T2=261.8±79.5 (p<0.05); IL-1 was T1=347.0±72.0, T2= 327.3±90.9 (p>0.05). The expression of TNF-α and IL-1 in the glomerular and tubular cells was significantly higher in the G2 group. CONCLUSIONS: Hemorrhage and glibenclamide elevated TNF-α and IL-1 concentrations in serum and kidneys. High levels of TNF-α already present before the hemorrhage in the glibenclamide group may have attenuated the damages found in the kidneys after the ischemia event.
Descritores: Choque Hemorrágico/metabolismo
Interleucina-1/metabolismo
Fator de Necrose Tumoral alfa/metabolismo
Glibureto/farmacologia
Hipoglicemiantes/farmacologia
Rim/efeitos dos fármacos
-Peso Corporal/efeitos dos fármacos
Distribuição Aleatória
Ratos Wistar
Anestésicos Inalatórios/administração & dosagem
Modelos Animais
Canais KATP/antagonistas & inibidores
Rim/irrigação sanguínea
Rim/metabolismo
Túbulos Renais/efeitos dos fármacos
Túbulos Renais/metabolismo
Éteres Metílicos/administração & dosagem
Limites: Animais
Responsável: BR1.1 - BIREME


  9 / 737 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-787262
Autor: Sahin, Hasan; Simsek, Tuncer; Turkon, Hakan; Kalkan, Yıldıray; Ozkul, Faruk; Ozkan, M Turgut Alper; Erbas, Mesut; Altinisik, Ugur; Demiraran, Yavuz.
Título: The acute effects of preoperative ozone theraphy on surgical wound healing
Fonte: Acta cir. bras;31(7):472-478tab, graf.
Idioma: en.
Resumo: ABSTRACT PURPOSE: To investigate the effects of preoperative rectal ozone insufflation on surgical wound healing over the proinflammatory cytokines and histopathological changes. METHODS: Twenty one rabbits were divided into 3 groups. Sham, surgical wound, and ozone applied (6 sessions, every other day 70 µg/mL in 12 mL O2-O3 mixture rectally) surgical wound groups were created. TNF-alpha and IL-6 levels from all rabbits were studied at the basal, 24th hour, and 72nd hour. The histopathological examination was done by removing the surgical scar tissue at the end of 72nd hour. RESULTS: TNF-alfa and IL-6 levels were significantly lower compared to the control group, in the rabbits treated with ozone. The increase in angiogenesis, the decrease in the number of inflammatory cells, epidermal and dermal regeneration, better collagen deposition, and increased keratinisation in stratum corneum were observed in the histopathological examination. It was determined that the wound healing noticeably accelerated in the ozone group. CONCLUSION: Preoperative rectal ozone insufflation had a positive effect on surgical wound healing in acute period.
Descritores: Ozônio/farmacologia
Cicatrização/efeitos dos fármacos
Interleucina-6/metabolismo
Fator de Necrose Tumoral alfa/metabolismo
Ferida Cirúrgica/tratamento farmacológico
-Ozônio/administração & dosagem
Cuidados Pré-Operatórios/métodos
Insuflação/métodos
Resultado do Tratamento
Ferida Cirúrgica/patologia
Tecido de Granulação/patologia
Anti-Inflamatórios/uso terapêutico
Limites: Animais
Coelhos
Responsável: BR1.1 - BIREME


  10 / 737 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-785012
Autor: Yılmaz, Edip Erdal; Bozdağ, Zübeyir; Ibiloğlu, Ibrahim; Arıkanoğlu, Zülfü; Yazgan, Ümit Can; Kaplan, Ibrahim; Gümüş, Metehan; Atamanalp, Sabri Selçuk.
Título: Therapeutic effects of ellagic acid on L-arginin induced acute pancreatitis
Fonte: Acta cir. bras;31(6):396-401tab, graf.
Idioma: en.
Resumo: ABSTRACT PURPOSE: To investigate the therapeutic effects of ellagic acid on L-arginin ınduced acute pancreatitis in rats. METHODS: Thirty-two were split into four groups. Group 1 (control) rats were performed only laparotomy, no drugs were administered. Group 2 (control+EA) rats were administered 85mg/kg EA orally. Rats were sacrificed by cardiac puncture 24 hours after the administration. Group3 (AP) 24 hours after intraperitoneal L-arginine administration, rats were sacrificed by cardiac puncture. Group 4 (EA)-(AP): 85mg/kg EA was administered orally after the L-arginine administration. 24 hours later, rats were sacrificed by cardiac puncture. Serum TNF-α, IL-1β, IL-6, total oxidative status (TOS), total antioxidant capacity (TAC), amylase levels were determined in all groups. RESULTS: Group 3 (AP) rats showed significantly raised TOS level as compared to Group1 (control) rats (p<0.001). Following the EA therapy, a decrease in TOS was observed in Group 4 (AP+EA). TAC levels were significantly raised in the Group 4 (AP+EA) compared to the Group 3 (AP) (p=0.003). Group 3 (AP) showed significantly increased TNF-α, IL-1β and IL-6 serum levels as compared to Group 4 (AP+EA). Histopathological changes were supported our result. CONCLUSION: The healing effects of ellagic acid on inflammatory and oxidative stress were confirmed by histopathological and biochemical evaluations of the pancreatic tissue.
Descritores: Pancreatite/tratamento farmacológico
Ácido Elágico/uso terapêutico
Anti-Inflamatórios/uso terapêutico
Antioxidantes/uso terapêutico
-Pancreatite/induzido quimicamente
Pancreatite/patologia
Pancreatite/sangue
Arginina
Distribuição Aleatória
Doença Aguda
Interleucina-6/sangue
Fator de Necrose Tumoral alfa/sangue
Ratos Sprague-Dawley
Estresse Oxidativo/efeitos dos fármacos
Ácido Elágico/farmacologia
Interleucina-1beta/sangue
Amilases/efeitos dos fármacos
Amilases/sangue
Anti-Inflamatórios/farmacologia
Antioxidantes/farmacologia
Limites: Animais
Masculino
Responsável: BR1.1 - BIREME



página 1 de 74 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde